Marisa Wexler, MS,  senior science writer—

Marisa holds a Master of Science in cellular and molecular pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. Her areas of expertise include cancer biology, immunology, and genetics, and she has worked as a science writing and communications intern for the Genetics Society of America.

Articles by Marisa Wexler

Repurposed drugs fail to slow disease progression in ALS trial

Neither memantine nor trazodone, two medications approved to treat other conditions, was able to slow disease progression in people with amyotrophic lateral sclerosis (ALS) who took part in a platform clinical trial, a study concluded. Based on the lack of benefits in the trial’s interim analysis, the two treatment…

Initiative to use AI technologies to improve communication in ALS

The Scott-Morgan Foundation (SMF), a nonprofit that’s pioneering assistive technology innovation, will lead a new initiative using artificial intelligence (AI) technologies to help people with diseases like amyotrophic lateral sclerosis (ALS) to better communicate and maintain their sense of identity. “We live in a world where millions are…

Brain-computer interface allows man with ALS to communicate

A brain-computer interface allowed Casey Harrell, a 45-year-old man with amyotrophic lateral sclerosis (ALS) whose disease had made it nearly impossible to speak, to communicate through a computer that used his own voice. Harrell’s experience in the ongoing pilot BrainGate2 clinical trial (NCT00912041) was described in the study,…

PrimeC normalizes iron biomarkers in Phase 2b ALS trial

One year of treatment with the experimental oral therapy PrimeC led to improved iron accumulation in people with amyotrophic lateral sclerosis (ALS), according to new clinical trial data announced by PrimeC’s developer, Neurosense Therapeutics. Previous results showed that people who received PrimeC for one year experienced significantly slower…